NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
14 déc. 2023 16h15 HE
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System
11 déc. 2023 08h00 HE
|
NeuroOne Medical Technologies Corp
First FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control; Marks the Company’s third...
NeuroOne® to Report Fourth Quarter and Fiscal Year 2023 Financial Results and Provide Corporate Update on December 14
07 déc. 2023 16h30 HE
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Dec. 07, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
16 nov. 2023 08h00 HE
|
NeuroOne Medical Technologies Corp
Patent allowance strengthens IP portfolio and positions company in pursuing drug delivery using its neural probes EDEN PRAIRIE, Minn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical...
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14 nov. 2023 17h15 HE
|
NeuroOne Medical Technologies Corp
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical...
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
07 nov. 2023 08h00 HE
|
NeuroOne Medical Technologies Corp
Feedback from responses to FDA anticipated in 30 days Commercialization remains on track in first half of 2024 pending FDA clearance Product potential for transformative improvement in...
NeuroOne® to Present at the ThinkEquity Conference on October 19, 2023
13 oct. 2023 09h30 HE
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Oct. 13, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
NeuroOne® to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 16h00 HE
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
14 août 2023 16h00 HE
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
NeuroOne® to Report Third Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on August 14
08 août 2023 16h00 HE
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...